Essential hypertension

被引:584
作者
Messerli, Franz H.
Williams, Bryan
Ritz, Eberhard
机构
[1] Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Div Cardiol, New York, NY 10019 USA
[2] Univ Leicester, Sch Med, Leicester, Leics, England
[3] Heidelberg Univ, Heidelberg, Germany
关键词
D O I
10.1016/S0140-6736(07)61299-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure >140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antibypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.
引用
收藏
页码:591 / 603
页数:13
相关论文
共 147 条
[61]   Should β blockers remain first choice in the treatment of primary hypertension?: A meta-analysis [J].
Lindholm, LH ;
Carlberg, B ;
Samuelsson, O .
LANCET, 2005, 366 (9496) :1545-1553
[62]   Does hypertension confer a prothrombotic state? Virchow's triad revisited [J].
Lip, GYH ;
Blann, AD .
CIRCULATION, 2000, 101 (03) :218-220
[63]   The Study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial [J].
Lithell, H ;
Hansson, L ;
Skoog, I ;
Elmfeldt, D ;
Hofman, A ;
Olofsson, B ;
Trenkwalder, P ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 2003, 21 (05) :875-886
[64]   Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure [J].
Liu, JE ;
Roman, MJ ;
Pini, R ;
Schwartz, JE ;
Pickering, TG ;
Devereux, RB .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (08) :564-+
[65]   Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial [J].
Lubsen, J ;
Wagener, G ;
Kirwan, BA ;
de Brouwer, S ;
Poole-Wilson, PA .
JOURNAL OF HYPERTENSION, 2005, 23 (03) :641-648
[66]  
MacMahon S, 2005, LANCET, V365, P1108
[68]   Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure [J].
Mancia, G ;
Facchetti, R ;
Bombelli, M ;
Grassi, G ;
Sega, R .
HYPERTENSION, 2006, 47 (05) :846-853
[69]  
Mancia G, 1997, CIRCULATION, V95, P1464
[70]   Systolic and diastolic blood pressure control in antihypertensive drug trials [J].
Mancia, G ;
Grassi, G .
JOURNAL OF HYPERTENSION, 2002, 20 (08) :1461-1464